Skip to main content
SpringerLink
Log in

Endothelin Ligands and their Experimental Effects Within the Human Circulation

  • Chapter
Endothelin and Its Inhibitors

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 152))

  • 127 Accesses

Abstract

A number of endothelin (ET) receptor antagonists have been developed as research tools and as potential medicines (see Chap. 9). Some of these are selective for the ETA or ETB receptor while others are mixed ETA/B receptor antagonists. Peptide antagonists are inactive orally and, therefore, of limited use as long term treatments. However, these compounds have been useful as research tools and are currently being developed as short term therapeutic agents. Due to ease of administration, non-peptide, orally active antagonists are more promising candidates for the treatment of chronic conditions and several are at various stages of clinical evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aellig WH (1981) A new technique for measuring compliance of human hand veins. Br J Clin Pharmacol 11:237–243

    Article  PubMed  CAS  Google Scholar 

  • Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg JM (1994) Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res 28:1559–1563

    Article  PubMed  CAS  Google Scholar 

  • Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D (1995) Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25:918–923

    Article  PubMed  CAS  Google Scholar 

  • Berrazueta JR, Bhagat K, Vallance P, MacAllister RJ (1997) Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 44:569–571

    Article  PubMed  CAS  Google Scholar 

  • Bradley SE (1987) Clearance concepts in renal physiology. In: Gottschalk CW, Berliner RW, Giebisch GH (eds) Renal Physiology — People and Ideas. American Physiological Society, Bethesda Maryland USA, pp 63–100

    Google Scholar 

  • Bussemaker E, Wichmann G, Passauer J, Gross P (1998) Role of endothelin and nitric oxide in the regulation of vascular tone in normotensive patients on chronic hemodialysis (Abstract). Circulation 98;Suppl 1:A1793

    Google Scholar 

  • Clark JG, Benjamin N, Larkin SW, Webb DJ, Keogh BE, Davies GJ, Maseri A (1989) Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 257: H2033–2035

    Google Scholar 

  • Cowburn PJ, Cleland JGF, MacArthur JD, MacLean MR, McMurray JJV, Dargie HJ (1998a) Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet 352:201–202

    Article  PubMed  CAS  Google Scholar 

  • Cowburn PJ, Cleland JGF, McDonagh A, MaArthur JD, MacLean MR, Dargie HJ (1998b) Adverse haemodynamic effects of a selective endothelin ETB receptor antagonist in patients with chronic heart failure: reversal with a selective endothelin ETA receptor antagonist (abstract). Circulation 98;Suppl 1:718

    Google Scholar 

  • Davenport AP, O’Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A (1993) Human endothelin receptors characterised using reverse transcriptase polymerase chain reaction, in-situ hybridisation and subtype selective ligands. BQ123 and BQ3020: evidence for expression of ET-B receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22 Suppl 8:S22–S25

    Article  PubMed  CAS  Google Scholar 

  • Douglas SA (1997) Meeting Report — Clinical development of endothelin receptor antagonists. TiPS 18:408–412

    PubMed  CAS  Google Scholar 

  • Ferro CJ, Webb DJ (1996a) The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 51:12–27

    Article  PubMed  CAS  Google Scholar 

  • Ferro CJ, Haynes WG, Hand MF, Webb DJ (1996b) The vascular endothelin and nitric oxide systems in essential hypertension. J Hypertens 14:S50

    Google Scholar 

  • Ferro CJ, Strachan FE, Plumpton C, Davenport AP, Cumming AD, Haynes WG, Webb DJ (1998) Actions of the Endothelin A/B Receptor Antagonist TAK-044 in Chronic Renal Failure. Nephrol Dial Trans 13:A66

    Article  Google Scholar 

  • Flynn DA, Sargent CA, Brazdil R, Brown TJ, Roach A (1995) Sarafotoxin S6c elicits a non-ETA or non-ETB mediated pressor response in the pithed rat. J Cardiovasc Pharmacol 26;Suppl 3:S219–221

    PubMed  CAS  Google Scholar 

  • Fukuroda T, Ozaki M, Ihara K, Ishikawa K, Yano M, Miyauchi T, Ishikawa S, Onizuka M, Goto K, Nishikibe M (1996) Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi. Br J Pharmacol 117:995–999

    Article  PubMed  CAS  Google Scholar 

  • Givertz MM, Colucci WS, Gottlieb SS, Hare JM, LeJemtel T, Slawsky MT, Leier CV, Loh E, Nicklas JM, Lewis BE (1998) Acute ETA receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure (abstract). Circulation 98;Suppl 1:578

    Google Scholar 

  • Gunal O, Yegen C, Aktan O, Yalin R, Yegen B (1996) Gastric function in portal hypertension: role of endothelin. Dig Dis Sci 41:585–590

    Article  PubMed  CAS  Google Scholar 

  • Hand MF, Haynes WG, Anderton JL, Winney R, Webb DJ (1994) Responsiveness of veins to endothelin-1 in chronic renal failure. Nephrol Dial Trans 9:1349–1350

    Google Scholar 

  • Hand MF, Haynes WG, Webb DJ (1999) Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure. Kidney Int 55:613–620

    Article  PubMed  CAS  Google Scholar 

  • Haynes WG, Webb DJ (1993a) Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci 84:427–433

    PubMed  CAS  Google Scholar 

  • Haynes WG, Webb DJ (1993b) Venoconstriction to endothelin-1 in humans: role of calcium and potassium channels. Am J Physiol 265:H1676–1681

    PubMed  CAS  Google Scholar 

  • Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ (1994a) Direct and sympathetically mediated venoconstriction in essential hypertension: enhanced response to endothelin. J Clin Invest 94:1359–1364

    Article  PubMed  CAS  Google Scholar 

  • Haynes WG, Webb DJ (1994b) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852–854

    Article  PubMed  CAS  Google Scholar 

  • Haynes WG, Moffat S, Webb DJ (1995a) An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Clin Pharmacol 40:307–311

    Article  PubMed  CAS  Google Scholar 

  • Haynes WG, Strachan FE, Webb DJ (1995b) Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92:357–363

    Article  PubMed  CAS  Google Scholar 

  • Haynes WG, Ferro CJ, O’Kane KPJ, Somerville D, Lomax CC, Webb DJ (1996) Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 93:1860–1870

    Article  PubMed  CAS  Google Scholar 

  • Hocher B, Thone-Reineke C, Bauer C, Raschack M, Neumayer HH (1997) The paracrine endothelin system: pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 35:175–189

    PubMed  CAS  Google Scholar 

  • Ihara M, Noguchi K Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M (1992) Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50:247–255

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M (1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91:4892–4896

    Article  PubMed  CAS  Google Scholar 

  • Jensen L, Yakimets J,Teo KK (1995) A review of impedance cardiography. Heart Lung 24:183–93

    Article  PubMed  CAS  Google Scholar 

  • Jilma B, Szalay T, Dirnberger E, Eichler HG, Stohlawetz P, Schwarzinger I, Kapiotis S, Wagner OF (1997) Effects of endothelin-1 on circulating adhesion molecules in man. Eur J Clin Invest 27:850–856

    Article  PubMed  CAS  Google Scholar 

  • Kaasjager KA, Shaw S, Koomans HA, Rabelink TJ (1997) Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Neph 8:32–39

    CAS  Google Scholar 

  • Kiely DG, Cargill RI, Struthers AD, Lipworth BJ (1997) Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 33:378–386

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi T, Ohtaki T, Kawata A, Imada T, Asami T, Masuda Y, Sugo T, Kusumoto K, Kubo K, Watanabe T, Wakimasu M, Fujino M (1994) Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB. Biochem Biophys Res Commun 200:1708–1712

    Article  PubMed  CAS  Google Scholar 

  • Kiowski W, Luscher TF, Linder L, Buhler FR (1990) Endothelin -1-induced vasoconstriction in humans, reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83:469–475

    Article  Google Scholar 

  • Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O (1995) Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 346:732–736

    Article  PubMed  CAS  Google Scholar 

  • Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784–790

    Article  PubMed  CAS  Google Scholar 

  • Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RH (1966) Development and evaluation of an impedance cardiac output system. Aerospace Med 37:1208–1212

    PubMed  CAS  Google Scholar 

  • Kyriakides ZS, Bofilis E, Tousoulis D, Antoniadis A, Kremastinos DTh, Webb DJ (1998) Endothelin-A receptor antagonist BQ123 provokes coronary vasodilatation and blood flow increases in humans (abstract) J Am Coll Cardiol 31

    Google Scholar 

  • Lampl Y, Fleminger G, Gilad R, Galron R, Sarova-Pinhas I, Sokolovsky M (1997) Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke. Stoke 28:1951–1955

    CAS  Google Scholar 

  • Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJ (1996a) Selective or nonselective endothelin receptor blockade in chronic heart failure? Circulation 94(Suppl I):2899–2900

    Google Scholar 

  • Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ (1996b) Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94:2131–2137

    Article  PubMed  CAS  Google Scholar 

  • Love MP, Haynes WG, Webb DJ, McMurray JJ (1996c) Endothelin receptor function in the capacitance vessels of patients with chronic heart failure. Circulation 94(Suppl I):2899–2900

    Google Scholar 

  • Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT (1992) Venous smooth muscle contains vasoconstrictor ET-B like receptors. Biochem Biophys Res Commun 184:100–106

    Article  PubMed  CAS  Google Scholar 

  • McCulloch KM, MacLean MR (1995) Endothelin B receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol 26 [Suppl 3]:S169–S176

    PubMed  CAS  Google Scholar 

  • McCulloch KM, Docherty C, MacLean MR (1998) Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Brit J Pharmacol 123:1621–1630

    Article  CAS  Google Scholar 

  • Nachev C, Collier J, Robinson B (1971) Simplified method for measuring compliance of superficial veins. Cardiovasc Res 5:147–156

    Article  PubMed  CAS  Google Scholar 

  • Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simon JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 9:944–949

    Google Scholar 

  • Nilsson GE, Tenland T, Oberg PA (1980) A new instrument for continuous measurement of tissue blood flow by light beating spectroscopy. IEEE Trans Biomed Eng BME-27:12–19

    Article  CAS  Google Scholar 

  • Nord EP (1997) Role of endothelin in acute renal failure. Blood Purification 15:273–285

    Article  PubMed  CAS  Google Scholar 

  • Packer M, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Massie B, McMurray J, Rizzon P, Swedberg K (1998) Multicenter, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure — results of the REACH-1 trial (abstract). Circulation 98 [Suppl 1]:3

    Google Scholar 

  • Pernow J, Kaijser L, Lundberg JM, Ahlborg G (1996) Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 94:2077–2082

    Article  PubMed  CAS  Google Scholar 

  • Peter MG, Davenport AP (1996) Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788,50235, Ro462005 and bosentan in the heart. Br J Pharmacol 117:455–462

    Article  PubMed  CAS  Google Scholar 

  • Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP (1996) The increase in human plasma immunoreactive endothelin but not endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 119:311–314

    Article  PubMed  CAS  Google Scholar 

  • Rabelink TJ, Kaasjager KAH, Boer P, Stroes EG, Braam B, Koomans HA (1994) Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 46:376–381

    Article  PubMed  CAS  Google Scholar 

  • Schmetterer L, Dallinger S, Bobr B, Selenko N, Eichler HG, Wolzt M (1998) Systemic and renal effects of an ETA receptor subtype-specific antagonist in healthy subjects. Br J Pharmacol 124:930–934

    Article  PubMed  CAS  Google Scholar 

  • Soper CPR, Latif AB, Bending MR (1996) Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 347:1842–1843

    Article  PubMed  CAS  Google Scholar 

  • Sorensen SS, Madsen JK, Pedersen EB (1994) Systemic and renal effects of intravenous infusion of endothelin-1 in healthy volunteers. Am J Physiol 266:F411–418

    PubMed  CAS  Google Scholar 

  • Spratt JCS, Goddard J, Labinjoh C, Strachan F, Patel N, Webb DJ (1999) The haemodynamic effects of systemic endothelin A receptor antagonism in healthy humans in vivo. Br J Clin Pharmacology 47:575P–620P

    Google Scholar 

  • Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ (1998) Systemic blockade of the ETB receptor increases peripheral vascular resistance in healthy men. Hypertension 33:581–585

    Article  Google Scholar 

  • Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS (1992) Endothelin ET-A and ET-B receptors mediated vascular smooth muscle contraction. Br J Pharmacol 107:858–860

    Article  PubMed  CAS  Google Scholar 

  • Sutsch G, Bertel O, Kiowski W (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 10:171–725

    Article  Google Scholar 

  • Sutsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, Kim JH, Rickenbacher P, Bertel O (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98:2262–2268

    Article  PubMed  CAS  Google Scholar 

  • Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H (1991) Presence of a non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Letters 282:103–106

    Article  PubMed  CAS  Google Scholar 

  • Thomas SHL (1992) Impedance cardiography using the Sramek-Bernstein method: accuracy and reproducibility at rest and during exercise. Br J Clin Pharmacol 34:467–476

    Article  PubMed  CAS  Google Scholar 

  • Uosaki Y, Yoshida M, Ogawa T, Saitoh YJ (1996) RES 1149–1 and -2, novel nonpeptidic endothelin B receptor antagonist produced by Aspergillus sp. II. Structure derivation. J Antibiotics 49:6–12

    Article  CAS  Google Scholar 

  • Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ (1998) Endothelin-A receptor antagonist mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752–756

    Article  PubMed  CAS  Google Scholar 

  • Vierhapper H, Wagner O, Nowotny P, Waldhausl W (1990) Effects of endothelin-1 in man. Circulation 81:1415–1418

    Article  PubMed  CAS  Google Scholar 

  • Vierhapper H, Wagner OF, Nowotny P, Waldhausl W (1991) Effect of endothelin-1 in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A. Eur J Clin Invest 22:55–59

    Article  Google Scholar 

  • Vierhapper H, Nowotny P, Waldhausl W (1995) Effects of endothelin-1 in man: impact on basal and adrenocorticotropin-stimulated concentrations of aldosterone. J Clin Endocrinol Metab 80:948–951

    Article  PubMed  CAS  Google Scholar 

  • Wang A, Bashore T, Holcslaw T, Freed M, Shusterman N (1998) Randomized prospective double blind multicenter trial of an endothelin receptor antagonist in the prevention of contrast nephrotoxicity. J Am Soc Nephrol 7:574A

    Google Scholar 

  • Watanabe Y, Naruse M, Monzen C, Naruse K, Ohsumi K, Horiuchi J et al. (1991) Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol 17 Suppl 7:S503–S505

    Article  PubMed  CAS  Google Scholar 

  • Webb DJ (1995) The pharmacology of human blood vessels in vivo. J Vasc Res 32:2–15

    Article  PubMed  CAS  Google Scholar 

  • Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marie SP, Peeters PAM, Jonkman JHG, Jones CR (1996) Pharmacokinetics and drug disposition: pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137

    Article  PubMed  CAS  Google Scholar 

  • Weitzberg E, Ahlborg G, Lundberg JM (1991) Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 180:1298–1303

    Article  PubMed  CAS  Google Scholar 

  • Wenzel RR, Noll G, Luscher TF (1994) Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 23:581–586

    Article  PubMed  CAS  Google Scholar 

  • Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Luscher TF (1996) Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 94:316–322

    Article  PubMed  CAS  Google Scholar 

  • Wenzel RR, Zbinden S, Noll G, Meier B, Luscher TF (1998a) Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide. Br J Clin Pharmacol 45:441–446

    Article  PubMed  CAS  Google Scholar 

  • Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, Jones R, Clozel M, Meier B, Luscher TF (1998b) Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98:2235–2240

    Article  PubMed  CAS  Google Scholar 

  • Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV (1991) Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 175:556–561

    Article  PubMed  CAS  Google Scholar 

  • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. J. Leslie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiac, Vascular and Inflammation Research, The William Harvey Research Institute St. Barthomew’s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK

    Timothy D. Warner Ph.D

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Leslie, S.J., Webb, D.J. (2001). Endothelin Ligands and their Experimental Effects Within the Human Circulation. In: Warner, T.D. (eds) Endothelin and Its Inhibitors. Handbook of Experimental Pharmacology, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56899-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56899-2_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63237-2

  • Online ISBN: 978-3-642-56899-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation